They have good news for lung cancer patients, the second most common cancer worldwide and one of the leading causes of death.
Taking Tagriso, also known as osimertinib, after surgery to remove a tumor reduces people’s risk of dying from a common lung cancer by 51%, according to new trial findings.
LiveScience.com The study reported results from a 682-patient trial involving participants diagnosed with non-small cell lung cancer (NSCLC), one of the two main types of primary lung cancer. All patients had a mutation in the epidermal growth factor receptor (EGFR) gene, which codes for a protein found on the surface of cells. EGFR mutations can increase a cancer’s ability to grow and spread, increasing patients’ risk of cancer recurrence after treatment.
The study was published on Sunday (June 4). New England Journal of Medicine, Adjuvant osimertinib conferred an overall survival benefit in patients with completely resected, EGFR-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC).
The American Society of Clinical Oncology (ASCO) meeting was held June 2-6 in Chicago, where researchers led by Yale University presented their findings.
“Thirty years ago, there was nothing we could do for these patients,” said Dr. Roy Herbst said at the ASCO meeting. The Guardian reported.
“Now we have this powerful drug. Fifty percent is a big deal in any disease, but certainly in a disease like lung cancer, it’s usually very resistant to treatments.”
Essentially, osimertinib blocks the effects of frequent EGFR mutations. About 25% of lung cancer patients worldwide carry these mutations Guardian